{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T05:13:12Z","timestamp":1737522792743,"version":"3.33.0"},"reference-count":26,"publisher":"Index Copernicus","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pol Przegl Chir"],"published-print":{"date-parts":[[2024,10,16]]},"abstract":"<jats:p>&lt;b&gt;Introduction:&lt;\/b&gt; Graves' disease (GD) is characterized by the presence of circulating TSH receptor antibodies (TRAb) in the blood and is currently the most common cause of hyperthyroidism. The most common extrathyroidal symptom of GD is Graves' ophthalmopathy (GO). Approximately 20\u201325% of patients with GD have clinically significant GO, whereas only 5% have moderate to severe one. The pathogenesis of GD and GO is related to each other, and the course of GO influences the choice of treatment modality.&lt;b&gt;Aim:&lt;\/b&gt; We compared the effects of radioactive iodine (RAI) and surgical treatment modalities used in the definitive treatment of patients with GD who have symptoms of the disease and GO.&lt;b&gt;Materials and methods:&lt;\/b&gt; Between January 2015 and December 2020, 119 patients who underwent definitive treatment for GD were identified, and those with GO symptoms had eye examinations before and after treatment. Demographic, clinical, pathological, and outcome data were collected from the hospital computer database.&lt;b&gt;Results:&lt;\/b&gt; Patients in the RAI group were older than the surgical group (49.6 and 41.8, p = 0.005). There was a significant difference between the two groups in the presence of GO (surgical 75.4% RAI 32.6%, p = 0.0001). After the first dose of RAI, 69.5% of the patients had remission. The overall remission rate after additional RAI was 95.6%. Total thyroidectomy was performed in all of the patients in the surgical group. GO was remarkable with a rate of 42.1% among the surgical treatment indications. Ocular symptoms were evaluated with CAS, disease severity, and proptosis. After definitive treatment, GO progression was observed at a rate of 21.8% (n = 10) in the RAI group and 8.8% (n = 5) in the surgical group.&lt;b&gt;Conclusions:&lt;\/b&gt; The surgical treatment in GD had a higher success rate compared to RAI treatment in cases with active GO. Surgery should be considered the primary and definitive treatment in patients with active GO. At the same time, Clinical Activity Score (CAS) was found to be more valuable than other parameters in the evaluation of treatment response in both groups.<\/jats:p>","DOI":"10.5604\/01.3001.0054.8003","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T11:46:42Z","timestamp":1736336802000},"page":"1-8","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of the clinical results of thyroidectomy and RAI treatment in the permanent treatment of Graves' disease"],"prefix":"10.5604","volume":"97","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0886-5693","authenticated-orcid":false,"given":"Alim","family":"Akbarov","sequence":"first","affiliation":[{"name":"Department of General Surgery, Liv Bona Dea Hospital, Baku, Azerbaijan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8667-1125","authenticated-orcid":false,"given":"Emrah","family":"Karatay","sequence":"additional","affiliation":[{"name":"Department of Radiology, Sureyyapasa Chest Diseases and Thoracic Surgery Research and Training Hospital, Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4288-0400","authenticated-orcid":false,"given":"Mirkhalig","family":"Javadov","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Medicana International Atasehir Hospital, Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5085-4763","authenticated-orcid":false,"given":"Hatice Deniz","family":"Ilhan","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Akdeniz University Faculty of Medicine, Antalya, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2627-3133","authenticated-orcid":false,"given":"Adil","family":"Boz","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Akdeniz University Faculty of Medicine, Antalya, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1912-0240","authenticated-orcid":false,"given":"Cumhur","family":"Ar\u0131c\u0131","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Akdeniz University Faculty of Medicine, Antalya, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3689","reference":[{"doi-asserted-by":"crossref","unstructured":"Antonelli A., Fallahi P., Elia G. et al. Graves\u2019 disease: Clinical manifestations,immune pathogenesis (cytokines and chemokines) and therapy. Best Pract ResClin Endocrinol Metab., 2020; 34(1): 101388. doi: 10.1016\/j.beem.2020.101388.","key":"624883r1","DOI":"10.1016\/j.beem.2020.101388"},{"doi-asserted-by":"crossref","unstructured":"Chung S.K., Asban A., Hur J., Iyer P., Chen H.: Hyperthyroidism Symptoms,Management, and Outcomes in Children and Adults Seeking DefinitiveSurgical Treatment. Ann Surg., 2021; 273(5): e181\u2013e182. doi: 10.1097\/SLA.0000000000004053.","key":"624883r2","DOI":"10.1097\/SLA.0000000000004053"},{"doi-asserted-by":"crossref","unstructured":"Elia G., Fallahi P., Ragusa F. et al.: Precision Medicine in Graves\u2019 Diseaseand Ophthalmopathy. Front Pharmacol., 2021; 12: 754386. doi: 10.3389\/fphar.2021.754386.","key":"624883r3","DOI":"10.3389\/fphar.2021.754386"},{"doi-asserted-by":"crossref","unstructured":"Laurberg P., Wallin G., Tallstedt L. et al.: TSH-receptor autoimmunity inGraves\u2019 disease after therapy with anti-thyroid drugs, surgery, or radioiodine:a 5-year prospective randomized study. Eur J Endocrinol., 2008; 158(1): 69\u201375.doi: 10.1530\/EJE-07-0450.","key":"624883r4","DOI":"10.1530\/EJE-07-0450"},{"doi-asserted-by":"crossref","unstructured":"Bahn R.S., Burch H.B., Cooper D.S. et al.: Hyperthyroidism and other causes ofthyrotoxicosis: management guidelines of the American Thyroid Associationand American Association of Clinical Endocrinologists. Endocr Pract., 2011;17(3): 456\u2013520. doi: 10.4158\/ep.17.3.456.","key":"624883r5","DOI":"10.4158\/EP.17.3.456"},{"doi-asserted-by":"crossref","unstructured":"Brand O.J., Gough S.C.: Genetics of thyroid autoimmunity and the role ofthe TSHR. Mol Cell Endocrinol., 2010; 322(1\u20132): 135\u2013143. doi:10.1016\/j.mce.2010.01.013.","key":"624883r6","DOI":"10.1016\/j.mce.2010.01.013"},{"doi-asserted-by":"crossref","unstructured":"Vejrazkova D., Vcelak J., Vaclavikova E. et al.: Genetic predictors of thedevelopment and recurrence of Graves\u2019 disease. Physiol Res., 2018; 67(Suppl 3):S431\u2013S439. doi: 10.33549\/physiolres.934018.","key":"624883r7","DOI":"10.33549\/physiolres.934018"},{"doi-asserted-by":"crossref","unstructured":"Kotwal A., Stan M.: Thyrotropin Receptor Antibodies-An Overview.Ophthalmic Plast Reconstr Surg., 2018; 34(4S Suppl 1): S20\u2013S27. doi: 10.1097\/IOP.0000000000001052.","key":"624883r8","DOI":"10.1097\/IOP.0000000000001052"},{"unstructured":"Gharib S., Moazezi Z., Bayani M.A.: Prevalence and severity of ocular involvementin Graves\u2019 disease according to sex and age: A clinical study from Babol, Iran.Caspian J Intern Med., 2018; 9(2): 178\u2013183. doi: 10.22088\/cjim.9.2.178.","key":"624883r9"},{"doi-asserted-by":"crossref","unstructured":"Smith T.J., Heged\u00fcs L.: Graves\u2019 Disease. N Engl J Med., 2016; 375(16): 1552\u2013 1565 doi: 10.1056\/NEJMra1510030.","key":"624883r10","DOI":"10.1056\/NEJMra1510030"},{"doi-asserted-by":"crossref","unstructured":"Burch H.B., Cooper D.S.: Management of Graves Disease: A Review. JAMA.,2015; 314(23): 2544\u20132554. doi: 10.1001\/jama.2015.16535.","key":"624883r11","DOI":"10.1001\/jama.2015.16535"},{"doi-asserted-by":"crossref","unstructured":"Ross D.S., Burch H.B., Cooper D.S. et al.: 2016 American Thyroid AssociationGuidelines for Diagnosis and Management of Hyperthyroidism and OtherCauses of Thyrotoxicosis. Thyroid., 2016; 26(10): 1343\u20131421. doi: 10.1089\/thy.2016.0229.","key":"624883r12","DOI":"10.1089\/thy.2016.0229"},{"doi-asserted-by":"crossref","unstructured":"Eckstein A.K., Plicht M., Lax H. et al.: Thyrotropin receptor autoantibodiesare independent risk factors for Graves\u2019 ophthalmopathy and help to predictseverity and outcome of the disease. J Clin Endocrinol Metab., 2006; 91(9):3464\u20133470. doi: 10.1210\/jc.2005-2813.","key":"624883r13","DOI":"10.1210\/jc.2005-2813"},{"doi-asserted-by":"crossref","unstructured":"Kahaly G.J., Bartalena L., Heged\u00fcs L. et al.: 2018 European Thyroid Association Guideline for the Management of Graves\u2019 Hyperthyroidism. Eur ThyroidJ., 2018; 7(4): 167\u2013186. doi: 10.1159\/000490384.","key":"624883r14","DOI":"10.1159\/000490384"},{"doi-asserted-by":"crossref","unstructured":"Bartalena L., Baldeschi L., Dickinson A. et al.: Consensus statement of the European Group on Graves\u2019 orbitopathy (EUGOGO) on management of GO. EurJ Endocrinol., 2008; 158(3): 273\u2013285. doi: 10.1530\/EJE-07-0666.","key":"624883r15","DOI":"10.1530\/EJE-07-0666"},{"doi-asserted-by":"crossref","unstructured":"Gough S.C.: The genetics of Graves\u2019 disease. Endocrinol Metab Clin NorthAm., 2000; 29(2): 255\u2013266. doi: 10.1016\/s0889-8529(05)70130-4.","key":"624883r16","DOI":"10.1016\/S0889-8529(05)70130-4"},{"doi-asserted-by":"crossref","unstructured":"Marin\u00f2 M., Latrofa F., Menconi F., Chiovato L., Vitti P.: Role of genetic andnon-genetic factors in the etiology of Graves\u2019 disease. J Endocrinol Invest.,2015; 38(3): 283\u2013294. doi: 10.1007\/s40618-014-0214-2.","key":"624883r17","DOI":"10.1007\/s40618-014-0214-2"},{"doi-asserted-by":"crossref","unstructured":"Tozzoli R., Bagnasco M., Giavarina D., Bizzaro N.: TSH receptor autoantibodyimmunoassay in patients with Graves\u2019 disease: improvement of diagnostic accuracy over different generations of methods. Systematic review and meta-analysis. Autoimmun Rev., 2012; 12(2): 107\u2013113. doi: 10.1016\/j.autrev.2012.07.003.","key":"624883r18","DOI":"10.1016\/j.autrev.2012.07.003"},{"doi-asserted-by":"crossref","unstructured":"Schott M., Morgenthaler N.G., Fritzen R. et al.: Levels of autoantibodies againsthuman TSH receptor predict relapse of hyperthyroidism in Graves\u2019 disease.Horm Metab Res., 2004; 36(2): 9296. doi: 10.1055\/s-2004-814217.","key":"624883r19","DOI":"10.1055\/s-2004-814217"},{"doi-asserted-by":"crossref","unstructured":"Elbers L., Mourits M., Wiersinga W.: Outcome of very long-term treatment with antithyroid drugs in Graves\u2019 hyperthyroidism associatedwith Graves\u2019 orbitopathy. Thyroid., 2011; 21(3): 279\u2013283. doi: 10.1089\/thy.2010.0181.","key":"624883r20","DOI":"10.1089\/thy.2010.0181"},{"doi-asserted-by":"crossref","unstructured":"Tanda M.L., Piantanida E., Liparulo L. et al.: Prevalence and natural history ofGraves\u2019 orbitopathy in a large series of patients with newly diagnosed graves\u2019hyperthyroidism seen at a single center. J Clin Endocrinol Metab., 2013; 98(4):1443\u20131449. doi: 10.1210\/jc.2012-3873.","key":"624883r21","DOI":"10.1210\/jc.2012-3873"},{"doi-asserted-by":"crossref","unstructured":"Cao J., Su Y., Chen Z., Ma C., Xiong W.: The risk factors for Graves\u2019 ophthalmopathy. Graefes Arch Clin Exp Ophthalmol., 2022; 260(4): 1043\u20131054. doi:10.1007\/s00417-021-05456-x.","key":"624883r22","DOI":"10.1007\/s00417-021-05456-x"},{"doi-asserted-by":"crossref","unstructured":"Gabriele R., Letizia C., Borghese M. et al.: Thyroid cancer in patients withhyperthyroidism. Horm Res., 2003; 60(2): 79\u201383. doi: 10.1159\/000071875.","key":"624883r23","DOI":"10.1159\/000071875"},{"doi-asserted-by":"crossref","unstructured":"Ren M., Wu M.C., Shang C.Z. et al.: Predictive factors of thyroid cancer in patients withGraves\u2019 disease. World J Surg., 2014; 38(1): 80\u201387. doi:10.1007\/s00268-013-2287-z.","key":"624883r24","DOI":"10.1007\/s00268-013-2287-z"},{"doi-asserted-by":"crossref","unstructured":"Boutzios G., Vasileiadis I., Zapanti E. et al.: Higher incidence of tall cell variant of papillary thyroid carcinoma in Graves\u2019 Disease. Thyroid., 2014; 24(2):347\u2013354. doi: 10.1089\/thy.2013.0133.","key":"624883r25","DOI":"10.1089\/thy.2013.0133"},{"doi-asserted-by":"crossref","unstructured":"Guo Z., Yu P., Liu Z., Si Y., Jin M.: Total thyroidectomy vs bilateral subtotal thyroidectomy in patients with Graves\u2019 diseases: a meta-analysis of randomized clinical trials. Clin Endocrinol (Oxf)., 2013; 79(5): 739\u2013746. doi: 10.1111\/cen.12209.","key":"624883r26","DOI":"10.1111\/cen.12209"}],"container-title":["Polish Journal of Surgery"],"original-title":[],"link":[{"URL":"https:\/\/ppch.pl\/gicid\/pdf\/01.3001.0054.8003","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ppch.pl\/gicid\/pdf\/01.3001.0054.8003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T11:13:06Z","timestamp":1737457986000},"score":1,"resource":{"primary":{"URL":"https:\/\/ppch.pl\/gicid\/01.3001.0054.8003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,16]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,9,18]]}},"URL":"https:\/\/doi.org\/10.5604\/01.3001.0054.8003","relation":{},"ISSN":["0032-373X","2299-2847"],"issn-type":[{"type":"print","value":"0032-373X"},{"type":"electronic","value":"2299-2847"}],"subject":[],"published":{"date-parts":[[2024,10,16]]}}}